InMode Ltd.

Good day and welcome to InMode's second quarter 2025 earnings results conference call. All participants will be in the listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, you may press star then two. Please note, this event is being recorded. I would now like to turn the conference over to Mary Sigal, CEO of MSIR. Please go ahead.

Thank you, operator, and everyone for joining us today. Welcome to InMount's second quarter 2025 earnings call. Before we begin, I would like to remind our listeners that certain information provided on this call may contain forward-looking statements, and the safe harbor statement outlined in today's earnings release also pertains to this call. If you have not received a copy of the release, please visit the investor relations section of the company's website. Changes in business, competitive, technological, regulatory, and other factors would cause actual results to differ materially from those expressed by the forward-looking statements made today. Our historical results are not necessarily indicative of future performance. As such, we can give no assurance as to the accuracy of our forward-looking statements and assume no obligation to update them except as required by law. With that, I'd like to turn the call over to Moshe Mizrahi, InMode's CEO. Moshe, please go ahead.

Thank you, Miri, and to everyone for joining us. With me today, Dr. Michael Quindel, our co-founder and chief technology officer, Yair Malka, our chief financial officer, and Rafael Likerman, our VP of finance. Following our prepared remark, we will all be available to answer your question. In the second quarter, we continue to navigate a challenging medical aesthetic market, especially in North America, due to reduced personal spending. This environment results in fewer treatments and less capital investment from physicians. consistent with the macroeconomic trend of recent quarters. Building on the strategy we outlined last year, we have started restructuring key part of our sales team to drive deeper market penetration. We have began by appointing a specialized manager and dedicated sales team focus on the envisioned platforms for the ophthalmology market. At the same time, We are strategically expanding our global footprint with new direct operation in Thailand and Argentina. These offices will enhance our local presence, improve customer support, and streamline operation compared to walking through distributors. Looking ahead, we are hosting a user meeting in late August to officially launch our new platforms in the wellness space. focus on increased blood circulation and pain relief for the urology community. We conducted a soft launch during Q2 and began introducing the platforms to selected users and gathered early feedback. The full commercial rollout will take place at the August event, and we anticipate initial revenue contribution in the fourth quarter. In closing, we will continue to navigate the current market challenges. We remain confident in in-mode offering and brand recognition, backed by a strong balance sheet and diversified portfolio and cutting-edge technology. We're well-positioned to continue leading the minimally invasive aesthetic and wellness industry. Now, I would like to turn the call over to Yair, our Chief Financial Officer. Yair.